Financial Performance - The company's operating revenue for Q1 2024 was CNY 111,382,482.48, representing a year-on-year increase of 57.38%[2] - The net profit attributable to shareholders was CNY 9,891,496.09, while the net profit after deducting non-recurring gains and losses was CNY -73,896,052.13[2] - The net profit for Q1 2024 was CNY 10,697,584.09, a significant recovery from a net loss of CNY 10,167,542.40 in Q1 2023, representing a turnaround of over 200%[17] - Operating profit for Q1 2024 was CNY 12,854,875.72, compared to an operating loss of CNY 4,455,052.87 in the same period last year, indicating a strong operational improvement[17] - The total comprehensive income for Q1 2024 was CNY 10,697,584.09, a significant improvement from a comprehensive loss of CNY 10,167,542.40 in Q1 2023[18] Cash Flow - The net cash flow from operating activities was CNY -49,777,576.25, indicating a significant cash outflow compared to the previous year[2] - Cash flow from operating activities showed a net outflow of CNY 49,777,576.25 in Q1 2024, worsening from a net outflow of CNY 17,869,040.15 in Q1 2023[20] - The company incurred a total operating cash outflow of CNY 226,912,360.08 in Q1 2024, compared to CNY 215,986,778.01 in Q1 2023, reflecting a slight increase in cash outflows[20] - The company reported cash and cash equivalents of CNY 270,573,241.18 at the end of Q1 2024, down from CNY 476,980,677.32 at the end of Q1 2023, indicating a decrease of approximately 43%[21] - The cash and cash equivalents decreased to RMB 319,197,396.68 from RMB 478,230,565.79, representing a decline of about 33.3%[12] - The company reported a decrease in cash flow from investing activities, with a net outflow of CNY 202,907,913.28 in Q1 2024, compared to a net outflow of CNY 386,659,252.68 in Q1 2023, indicating reduced investment expenditures[20] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 3,991,401,796.65, a 1.94% increase from the end of the previous year[3] - The total assets as of March 31, 2024, were RMB 3,991,401,796.65, compared to RMB 3,915,297,259.57 as of December 31, 2023, showing a growth of about 1.9%[14] - The total liabilities as of March 31, 2024, were RMB 2,896,201,970.86, an increase from RMB 2,815,714,892.79 at the end of 2023, which is an increase of approximately 2.9%[14] - The equity attributable to shareholders decreased by 0.47% to CNY 1,091,114,016.87 compared to the end of the previous year[3] - The company’s equity attributable to shareholders was RMB 1,091,114,016.87 as of March 31, 2024, slightly down from RMB 1,096,302,645.86 at the end of 2023[15] Revenue and Costs - The total operating revenue for Q1 2024 was RMB 111,382,482.48, representing an increase from RMB 70,774,875.02 in Q1 2023, which is a growth of approximately 57.5%[16] - The total operating costs for Q1 2024 were RMB 187,332,029.36, up from RMB 77,812,036.40 in Q1 2023, indicating a significant increase of about 140.5%[16] - The gross profit margin for Q1 2024 was negative, with a gross loss of RMB 73,828,146.74 compared to a gross profit of RMB 51,479,299.85 in Q1 2023[16] - Sales revenue from goods and services received in Q1 2024 was CNY 88,367,912.72, up from CNY 73,290,998.65 in Q1 2023, marking an increase of about 20.6%[19] Research and Development - Research and development expenses for Q1 2024 amounted to RMB 15,448,941.63, compared to RMB 10,342,213.08 in Q1 2023, reflecting an increase of approximately 49.5%[16] Government Support - The company received government subsidies amounting to CNY 82,404,439.61, contributing to the financial performance during the quarter[5] Shareholder Returns - The basic and diluted earnings per share were both CNY 0.03[2] - The basic and diluted earnings per share for Q1 2024 were both CNY 0.03, recovering from a loss of CNY 0.04 per share in Q1 2023[18] - The weighted average return on equity increased by 1.7 percentage points to 0.90%[2] Business Focus - The increase in operating revenue was primarily driven by the launch of new photovoltaic business activities[6] - The company is currently focusing on expanding its photovoltaic business, which has begun production and is expected to contribute to future revenue growth[7]

Financial Performance - In 2023, the company reported a net profit attributable to shareholders of -269,419,361.74 CNY, while the parent company achieved a net profit of 23,458,129.15 CNY[5]. - The company plans not to distribute profits for 2023 due to overall performance losses and considerations for stable future development[5]. - The net profit attributable to shareholders of the listed company was -¥269,419,361.74, a decrease of 902.79% from ¥33,560,503.99 in the previous year[22]. - The net cash flow from operating activities was -¥316,649,274.19, down 726.86% from ¥50,513,364.11 in 2022[22]. - The total profit was -261.99 million yuan, a year-on-year decrease of 701.50%[70]. - The company reported a net loss of 281.57 million RMB for the period, attributed to high upfront investments in new photovoltaic business and increased personnel costs[148]. Revenue and Growth - The company's operating revenue for 2023 reached ¥618,141,465.76, representing a 102.33% increase compared to ¥305,507,310.15 in 2022[22]. - The company achieved operating revenue of CNY 618.14 million in 2023, a growth of 102.33% year-on-year[32]. - The photovoltaic business generated operating revenue of ¥300,057,198.99, with an operating cost of ¥403,711,613.54, resulting in a gross margin of -34.54%[76]. - The software and information services achieved revenue of 260.29 million yuan, a year-on-year increase of 1.85%, with a gross margin of 78.83%, up 2.91 percentage points[78]. - Medical services generated revenue of 56.60 million yuan, a year-on-year increase of 16.24%, with a gross margin of 41.38%, down 0.54 percentage points due to the expansion of service offerings and increased personnel costs[78]. Investments and Assets - The total assets increased by 140.14% to ¥3,915,297,259.57 from ¥1,630,417,953.78 in 2022[22]. - By the end of 2023, the net assets attributable to shareholders decreased by CNY 259.68 million, a decline of 19.15% due to overall losses[25]. - The company’s investment in construction projects reached ¥1,246,408,821.03, representing 31.83% of total assets, primarily for new photovoltaic production lines[126]. - The company has a total of 174,432.98 million RMB in ongoing production line investments, with the remaining capacity expected to be put into production gradually[137]. Strategic Developments - The company entered the new energy photovoltaic industry, with a focus on a 9GW N-type TOPCon photovoltaic cell project, achieving market-leading product performance[31]. - The company signed an investment agreement to build a 9GW high-efficiency monocrystalline battery factory in Mianyang, Sichuan, with the first production line achieving operational status in May 2023[49]. - The company is focused on leveraging data analytics to enhance clinical outcomes and operational efficiencies in healthcare settings[104][105]. - The company aims to enhance its competitive edge through technological advancements in clinical decision support systems[104]. Governance and Compliance - The audit report issued by Zhonghui Certified Public Accountants confirmed the financial report's authenticity and completeness[4]. - The report indicates that the board of directors and management are committed to ensuring the accuracy and integrity of the annual report[7]. - The company has established a comprehensive internal control system, revising multiple governance documents to enhance risk management capabilities[178]. - The company held 5 shareholder meetings during the reporting period, with 28 proposals approved[176]. Market Position and Competition - The market share of N-type batteries has rapidly increased to 25.6% in 2023, with expectations to exceed 50% in 2024[43]. - The photovoltaic industry is experiencing structural overcapacity, leading to price declines and increased competition, which poses risks to the company's market strategies[169]. - The company’s N-type TOPCon battery technology is expected to capture over 50% market share by 2024, but rapid technological advancements in the industry present risks[170]. Research and Development - The company has obtained a total of 2 authorized patents during the reporting period, including 1 invention patent and 35 new software copyrights[36]. - The company is actively collaborating with research institutions and industry partners to enhance its R&D capabilities in AI and other advanced technologies[61]. - The company completed the development of a non-contact vital signs monitoring system using millimeter-wave radar sensor technology, with an investment of ¥3.88 million[104]. Challenges and Risks - The company faced challenges in the photovoltaic sector due to price fluctuations and high initial investments, leading to overall losses despite stable performance in its medical information and assisted reproduction businesses[74]. - The company is at risk of losing technological and market advantages if it fails to keep pace with rapid software updates and evolving market demands[165]. - Changes in domestic and international policies regarding energy subsidies and trade could adversely affect the photovoltaic industry and the company's performance[171].

证券代码：603990 证券简称：麦迪科技 公告编号：2024-031 苏州麦迪斯顿医疗科技股份有限公司 公司使用闲置募集资金购买的产品不存在逾期未收回的情况。截至本公告 披露日，公司使用募集资金购买产品的余额为0万元。 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日召开第四届董事会第六次会议、第四届监事会第三次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金 投资项目进度和募集资金安全的前提下，对暂时闲置的部分募集资金不超过人民 币 3 亿元（包含本数）进行现金管理，余额在上述额度内，资金可以滚动使用， 用于购买单笔期限最长不超过 12 个月（含 12 个月）的结构性存款、大额存单等 安全性高的保本型产品，不得用于证券投资。公司独立董事、监事会及保荐机构 已分别对前述事项发表了同意的意见。具体内容详见公司于 2023 年 4 月 29 日披 露的 ...

Group 1: Company Overview - Suzhou MediTech focuses on smart medical care in critical conditions, with over 2,300 medical institutions covered across 32 provinces in China [3][4] - The company has been dedicated to medical information technology and health product development since 2005, holding over 80% market share in the high-end market [5][6] Group 2: Strategic Partnerships - MediTech plans to collaborate with Zhongke Xingzhi and Fourier to form a technical team for market application, integrating resources for technology development, application scenarios, and market promotion [4][6] - The partnership aims to leverage each company's strengths in medical scenarios, AI algorithms, and humanoid robotics to enhance service robots in the healthcare industry [6] Group 3: Product Development and Market Strategy - The company aims to develop various robots for different healthcare scenarios, including nursing robots, ward patrol robots, and companionship robots [5][6] - Specific plans include launching a prototype by the end of 2024, with development phases including application scenario identification and technical joint development in Q2 and prototype testing in Q3 [4][6] Group 4: Production Capacity and Efficiency - The 9GW production capacity was completed in Q4 2023, currently operating at 60-70% capacity, driven by market demand [7] - The company targets a production line efficiency increase to 26.7% by the end of the year, with current average efficiency at 26% [7] Group 5: Financial Performance and Shareholder Returns - The company has actively distributed dividends, with cash dividends of 10.7663 million yuan in 2020 and share repurchases totaling 70.6919 million yuan in 2021 [8] - As of March 31, 2024, the company repurchased shares worth 18.0675 million yuan [8]

证券代码：603990 证券简称：麦迪科技 公告编号：2024-030 苏州麦迪斯顿医疗科技股份有限公司 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日召开第四届董事会第六次会议、第四届监事会第三次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金 投资项目进度和募集资金安全的前提下，对暂时闲置的部分募集资金不超过人民 币 3 亿元（包含本数）进行现金管理，余额在上述额度内，资金可以滚动使用， 用于购买单笔期限最长不超过 12 个月（含 12 个月）的结构性存款、大额存单等 安全性高的保本型产品，不得用于证券投资。公司独立董事、监事会及保荐机构 已分别对前述事项发表了同意的意见。具体内容详见公司于 2023 年 4 月 29 日披 露的《关于使用部分闲置募集资金进行现金管理的公告》(公告编号：2023-043)。 特此公告。 苏州麦迪斯顿医疗科技股份 ...

一、 公司募集资金现金管理到期赎回情况 公司于 2024 年 1 月 3 日分别向浙商银行苏州分行营业部、江阴农商银行苏 州分行办理了结构性存款业务。截至本公告披露日，公司已将上述产品赎回，收 回本金 9,900 万元，获得理财收益 50.26 万元。 上述产品具体情况如下： 单位：人民币万元 苏州麦迪斯顿医疗科技股份有限公司 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日召开第四届董事会第六次会议、第四届监事会第三次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金 投资项目进度和募集资金安全的前提下，对暂时闲置的部分募集资金不超过人民 币 3 亿元（包含本数）进行现金管理，余额在上述额度内，资金可以滚动使用， 用于购买单笔期限最长不超过 12 个月（含 12 个月）的结构性存款、大额存单等 安全性高的保本型产品，不得用于证券投资。公司独立董事、监 ...

一、 增持主体的基本情况 （一）增持主体：公司监事会主席李彪先生 证券代码：603990 证券简称：麦迪科技 公告编号：2024-028 苏州麦迪斯顿医疗科技股份有限公司 关于公司监事会主席增持股份计划实施完毕暨增持结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增持计划的基本情况：基于对公司内在价值的认可，公司监事会主席李 彪先生计划自 2024 年 2 月 1 日至 2024 年 7 月 31 日增持公司股份，拟增持金额 不低于人民币 50 万元且不超过人民币 100 万元。具体内容详见公司于 2024 年 2 月 1 日披露的《麦迪科技关于公司监事会主席、副总经理增持股份计划的公告》 （公告编号：2024-005）。 增持计划的实施结果：公司于 4 月 7 日收到公司监事会主席李彪先生发 来的《关于增持股份计划实施完毕的告知函》，其本次股份增持计划已实施完毕。 2024 年 2 月 1 日至 2024 年 4 月 7 日，李彪先生以集中竞价方式累计增持公司股 份 50,700 股，占公司当前总 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603990 证券简称：麦迪科技 公告编号：2024-026 苏州麦迪斯顿医疗科技股份有限公司 以集中竞价交易方式回购股份的进展公告 一、 回购股份的基本情况 二、 回购股份的进展情况 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出回 购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务，敬 请广大投资者注意投资风险。 重要内容提示： 特此公告。 | 回购方案首次披露日 | 2024/2/7 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 | 2 月 6 | 日~2024 | 年 | 8 | 月 5 | 日 | | 预计回购金额 | 1,500 | 万元~3,000 | 万元 | | | | | | 回购用途 | | 用于员工 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2024-025 苏州麦迪斯顿医疗科技股份有限公司 关于提供对外担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 公司担保情况概述 （一） 对外担保的审议情况 公司于2023年4月27日、2023年5月19日，分别召开了第四届董事会第六次会 议、2022年年度股东大会，审议通过了《关于预计2023年度为子公司提供担保额 度的议案》，同意公司为全资子公司炘皓新能源新增担保额度7亿元。上述担保 被担保人名称：绵阳炘皓新能源科技有限公司（以下简称"炘皓新能 源"）,为苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"） 全资子公司。 本次担保金额及已实际为其提供的担保余额：本次为炘皓新能源提供 的担保金额为 9,650 万元；截止 2024 年 3 月 31 日，已实际为其提供 的担保余额为 54,010.97 万元（含本次）。 本次担保是否有反担保：否 对外担保逾期的累计数量：无 特别风险提示：被担保人绵阳炘皓新能源科技有限公司的资产负债率 ...